To succeed in China’s dynamic pharmaceutical landscape, you must first have a good understanding of the China National Medical Products Administration (NMPA), how China regulates drugs, and China’s pharmaceutical Good Manufacturing Practices (GMP) regulations.

Speaker: Andrew Chen, J.D.

Chief Representative, Shanghai Office of Arnold & Porter LLP. Mr. Chen is a seasoned expert with over two decades of experience, including serving at the US FDA and Amgen.

In this webinar, you can expect to learn about:

• The NMPA as a government agency.
• Chinese approach to drug approval and oversight.
• Chinese pharmaceutical GMP regulations.

During the presentation, the speaker will draw comparisons between China’s NMPA and the US FDA, aiming to enhance comprehension for individuals familiar with the US FDA. With the speaker’s distinctive expertise in both US and Chinese law, he has the capacity to distill complex topics into a simple, organized, and easily understandable presentation.

Who Should Attend:

• Pharmaceutical professionals whose job responsibilities or professional interests involve China.
• Pharmaceutical professionals in RA, QA, medical, commercial, business development, and legal functions.
• Pharmaceutical professionals at all levels of experience, from entry to executive levels.

Register Now!